<DOC>
	<DOCNO>NCT00982449</DOCNO>
	<brief_summary>This research do determine whether viral thymidine kinase ( TK ) expression Epstein-Barr virus ( EBV ) Kaposi 's sarcoma herpesvirus ( KSHV ) virus-associated tumor sufficient image .</brief_summary>
	<brief_title>124I-FIAU Imaging EBV KSHV Associated Cancers</brief_title>
	<detailed_description>EBV KSHV associate variety malignancy include lymphoma , carcinoma malignancy . We anticipate viral TK expression differ among tumor type adjust standard chemotherapy investigational agent . This exploratory study aim part evaluate whether standard regimen investigational regimen might bring sufficient activation EBV-TK KSHV-TK tumor therapeutically useful use conjunction FIAU radiopharmaceutical .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Fialuridine</mesh_term>
	<criteria>1 . Age 18 year old . 2 . EBVpositive KSHVassociated malignancy , include limited : EBV+ Hodgkin lymphoma EBV+ nonHodgkin lymphoma lymphoproliferative disease Primary effusion lymphoma Kaposi 's sarcoma EBV+ gastric cancer EBV+ nasopharyngeal cancer 3 . Measurable disease ( least one lesion measure &gt; 2 cm long axis ) . 4 . ECOG performance status 0 , 1 , 2 . 5 . Patients must able lie flat least 60 minute fit PETCT scanner . 6 . For posttherapy imaging FIAUPET , treatment standard investigational agent potentially activate herpesvirus TK , include limited following . Concurrent radiation therapy permissible : Platinum compound ( example , cisplatin , carboplatin ) Anthracyclines ( example , doxorubicin pegylated doxorubicin ) Tubulin disrupt agent ( example , vincristine , vinblastine ) Rituximab Gemcitabine Cytarabine Histone deacetylase inhibitor Bortezomib NOTE : Patients would receive bortezomib part usual care may receive onetime dose bortezomib purpose image 124IFIAU FIAUPETCT . 7 . AST ALT &lt; 3 X upper limit normal , unless attribute tumor , obtain within 2 week prior registration . 8 . Serum creatinine &lt; 2.0 mg/dL , within 2 week prior registration . 9 . In patient receive bortezomib image purpose : Total bilirubin &lt; 1.5 X upper limit normal , obtain within 2 week prior registration . Platelet count &gt; 70,000 / mm3 obtain within 2 week prior registration . No preexist peripheral neuropathy great grade 1 . 1 . Endstage liver disease unrelated tumor . 2 . Known active chronic hepatitis B hepatitis C infection . 3 . History iodine hypersensitivity . 4 . Chronic renal insufficiency require dialysis . 5 . Women pregnant breast feeding . 6 . Foreseen inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>EBV+ malignancy</keyword>
	<keyword>KSHV+ malignancy</keyword>
	<keyword>HIV-associated lymphoma</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>nonHodgkin Lymphoma</keyword>
	<keyword>nonHodgkins Lymphoproliferative Disease</keyword>
	<keyword>Primary Effusion Lymphoma</keyword>
	<keyword>Kaposi 's Sarcoma</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Nasopharyngeal Cancer</keyword>
</DOC>